CTi Biopharma Corp

CTi Biopharma — Cell Therapeutics — JP Morgan Healthcare Conference 2010

22 slides from CTi Biopharma's conference presentation, Jan 11, 2010

  1. Slide 1: JP Morgan Healthcare Conference

    Slide 1: JP Morgan Healthcare Conference

    JP Morgan Healthcare Conference January, 2010 James A. Bianco, M.D. Chief Executive Officer Exhibit 99.1

  2. Slide 2: Forward Looking Statement

    Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this presentation include statements about future financial and oper

  3. Slide 3: Overview

    Slide 3: Overview

    Overview Focused on Profitability Pixantrone: a potential breakthrough therapy for aNHL Potential to become the anthracycline of choice ODAC panel February th • Accelerated approval requested based on FDA guidance • Proposed PMC trials under review by FDA • Label and carton discussions in progress M

  4. Slide 4: A Powerful Cancer Drug Portfolio

    Slide 4: A Powerful Cancer Drug Portfolio

    A Powerful Cancer Drug Portfolio 3rd line relapse aggressive NHL 1st line Ovarian cancer 1st line aggressive NHL 1st line Esophageal cancer +XRT Preclinical Phase I Phase II Phase III Marketed NDA review PH 2-3 completed Phase 3 Phase 2-3 Brostallicin Bisplatinates

  5. Slide 5: Opportunity Assessment

    Slide 5: Opportunity Assessment

    Opportunity Assessment Anthracyclines – 3 rd most commonly used class cytotoxics >300,000 pts receive anthracyclines each year Potentially curative in NHL, leukemia, breast cancer Cornerstone 1 st line therapy (CHOP-R) incorporates an anthracycline in 80% of the 32,000 pts/yr with aNHL Opportunity A

  6. Slide 6: Heart Failure Limits Re-treatment

    Slide 6: Heart Failure Limits Re-treatment

    Heart Failure Limits Re-treatment Heart Failure Limits Re-treatment

  7. Slide 7: Best in Class Next Generation Anthracycline

    Slide 7: Best in Class Next Generation Anthracycline

    Best in Class Next Generation Anthracycline Mitoxantrone Doxorubicin Rationally Designed to Improve Effectiveness and Reduce Cardiotoxicity Faster forming , more stable DNA adduct formation Significant reduction in cardiac damage in animal models Vs Dox/Mitox Inability to generate free radicals, or

  8. Slide 8: Encouraging CR rates in NHL

    Slide 8: Encouraging CR rates in NHL

    Encouraging CR rates in NHL Overall response rate, % AZA I-03 NHL/CLL n = 26 AZA II-01 Aggressive NHL n = 33 AZA-I-05 Aggressive NHL n = 19 AZA I-06 Indolent NHL FPDR n = 28 AZA I-07 Phase I aNHL CPOP - n = 31 AZA I-07 Phase II aNHL CPOP n = 30 Encouraging CR rates in NHL Single agent studies Combin

  9. Slide 9: PIX 301 Phase III Study Design

    Slide 9: PIX 301 Phase III Study Design

    PIX 301Phase III Study Design - 1 st Randomized Controlled Phase III trial - Relapsed or refractory aggressive NHL >2 nd relapse - 140 patients Primary Endpoint* - Complete Remission (CR/CRu) Secondary Endpoints* - Overall Response Rate (ORR) - Responses > 4months - Time to response - Progression Fr

  10. Slide 10: Summary PIX301 Phase III Results

    Slide 10: Summary PIX301 Phase III Results

    Summary PIX301 Phase III Results End of Treatment Evaluation *All response and progression data determined by blinded Independent Assessment Panel (IAP) Superior efficacy over standard of care Superior CR rates 20% Vs. 5.7% p=0.021 Superior ORR 37% Vs. 14.3% p=0.003 Superior PFS 4.7 months Vs. 2.6 m

  11. Slide 11: Lifetime Anthracycline Exposure (Doxorubicin Equivalent Dose)

    Slide 11: Lifetime Anthracycline Exposure (Doxorubicin Equivalent Dose)

    Lifetime Anthracycline Exposure (Doxorubicin Equivalent Dose) Treatment Cycle Lifetime Cumulative Dose** Occurrence Congestive Heart Failure N Median (mg/m 2 ) 1 68 365.2 2/68 2 54 430.2 0/54 3 43 498.1 2/43 4 36 571.8 0/36 5 25 631.5 1/25 6 22 695.0 0/22 * Pixantrone dose converted to dox equivalen

  12. Slide 12: PIX301 CR/CRu End of Treatment Vs Follow-up

    Slide 12: PIX301 CR/CRu End of Treatment Vs Follow-up

    PIX301 CR/CRu End of Treatment Vs Follow-up End of Treatment > 9 month Follow-up *IAP determined, Intent to Treat

  13. Slide 13: PIX301 PFS End of Treatment Vs Follow-up

    Slide 13: PIX301 PFS End of Treatment Vs Follow-up

    Median PFS 5.6 Vs 2.6 months HR 0.56 (p=0.002) *IAP determined, Intent to Treat PIX301 PFS End of Treatment Vs Follow-up Median PFS 4.7 Vs 2.6 months HR 0.60 (p=0.007) End of Treatment > 9 month Follow-up Pixantrone Standard Chemotherapy Pixantrone Standard Chemotherapy

  14. Slide 14: PIX301 OS End of Treatment Vs Follow-up

    Slide 14: PIX301 OS End of Treatment Vs Follow-up

    Median Overall Survival 10.2 Vs 6.9 months HR 0.82 (p=0.3) *IAP determined, Intent to Treat > 9 month Follow-up Median Overall Survival 8.1 Vs 6.9 months HR 0.88 (p=0.5) End of Treatment PIX301 OS End of Treatment Vs Follow-up Pixantrone Standard Chemotherapy Pixantrone Standard Chemotherapy

  15. Slide 15: Commercial Opportunity

    Slide 15: Commercial Opportunity

    15 Commercial Opportunity

  16. Slide 16: Commercial Analysis Assumptions

    Slide 16: Commercial Analysis Assumptions

    Assumptions Pricing $24/mg – $1,200 vial, = average use 36 vials/patient Exclusivity in the market to 2018 (US) / 2020(EU) Regulatory approval – aggressive relapsed NHL US early Q2-2010, EU 2011 Modeling assumptions (US only) Only NHL is included 1 line 32,029 patients 2 line 10,150 patients 3 line

  17. Slide 17: Novartis – CTI Agreement(s)

    Slide 17: Novartis – CTI Agreement(s)

    Novartis – CTI Agreement(s) NVS has option to negotiate a license to pixantrone Provides $104 million in registration/sales milestones $17.5mm on approval for r/r aNHL 28% to 32% royalty on net sales NVS assumes certain costs and pays CTI to field 35 sales people CTI not obligated to license pixantr

  18. Slide 18: Opaxio

    Slide 18: Opaxio

    (POPAXIO" Wcth

  19. Slide 19: Opaxio Regulatory Status

    Slide 19: Opaxio Regulatory Status

    Opaxio Regulatory Status Pivotal trial (GOG212) • GOG to conduct an interim “futility” PFS analysis in 1H 2010 • Market size 15,000 to 20,000 patients/year Additional registration trial in lower esophageal cancer • XRT sensitization • Impressive rates of (45%) pathologic complete remission rates wit

  20. Slide 20: Novartis–CTI Agreement(s)

    Slide 20: Novartis–CTI Agreement(s)

    Novartis–CTI Agreement(s) Worldwide license to OPAXIO • Reimburses for 50% of certain expenses • $270M in potential registration and sales milestones • CTI to field 35 FTE at NVS expense up to $9M • NVS to assume certain development and commercial expenses • Royalties 20%-25% on WW net sales

  21. Slide 21: Capital Structure/Financials

    Slide 21: Capital Structure/Financials

    Capital Structure/Financials Dual Listed NASDAQ:CTIC, MTA:CTIC.M I • Liquid stock ~30mm shares/day US/EU (3 month average ) • 587mm shares outstanding • week share price ($0.05 - $2.23) • Current price $1.20/share Cleaned up Balance Sheet and Capital Structure • Exchanged $57.4mm debt Cut Burn Rate

  22. Slide 22: Upcoming Events

    Slide 22: Upcoming Events

    Upcoming Events Upcoming Events ODAC meeting - Feb. 10, 2010 Potential NDA approval of Pixantrone File pixantrone MAA in Europe - mid 2010 GOG futility PFS analysis on st line maintenance trial with OPAXIO ASCO pixantrone launch SPA Meeting with FDA for Registration Study of OPAXIO as Radiation Sens

Source: SEC EDGAR · 8-K filed Jan 11, 2010

More decks from CTi Biopharma Corp